This indicates that a substantial proportion of African women diagnosed of breast cancer are unable to benefit from anti-ER nor anti-HER2 adjuvant therapies and, in the absence of alternative molecular targets, must resort to conventional chemotherapy. Here, ESR1 is linked to breast cancer.